As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
14 Analysts have issued a Unicycive Therapeutics Inc forecast:
14 Analysts have issued a Unicycive Therapeutics Inc forecast:
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -32 -32 |
55%
55%
|
|
| EBIT (Operating Income) EBIT | -32 -32 |
55%
55%
|
|
| Net Profit | -38 -38 |
20%
20%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
| Head office | United States |
| CEO | Shalabh Gupta |
| Employees | 23 |
| Founded | 2016 |
| Website | unicycive.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


